Company Encyclopedia
View More
name
Indivior PLC
INDV.UK
News
View More

Indivior PLC Proposes Re-Domiciliation to Delaware

Indivior PLC announced plans to re-domicile from the U.K. to Delaware, U.S., establishing Indivior Pharmaceuticals, Inc. as the new holding company. This move aims to enhance U.S. capital market presence and simplify governance. Shareholders will vote on this proposal on December 11, 2025. If approved, Indivior Pharmaceuticals shares will replace Indivior shares on Nasdaq, aligning with the U.S.-based majority shareholder base.

TradingView·
UK
INDV
0.00%
TradingView·
UK
INDV
0.00%

3 Top Ranked Stocks That Are The Best Of The Best

This week, Zacks stock strategist Tracey Ryniec highlights three top-ranked stocks with a Zacks #1 Strong Buy rating and an A in the VGM score. The stocks include Indivior PLC, which focuses on opioid treatment and expects earnings to rise 30.1% in 2025; The Travelers Companies, a property and casualty insurer with a projected 14.6% earnings increase; and OppFi Inc., a digital finance platform anticipating a 65.3% earnings jump. All three stocks show strong fundamentals and attractive valuations.

Talkmarkets·
UK
INDV
0.00%
Talkmarkets·
UK
INDV
0.00%

Indivior (INDV) Is Up 25.9% After Strong Q3 Results and Raised Revenue Guidance Has The Bull Case Changed?

Indivior PLC's shares surged 25.9% following strong Q3 results, with net income doubling to $42 million and sales reaching $314 million. The company raised its 2025 revenue guidance to $1.18-$1.22 billion, bolstered by positive real-world evidence for its SUBLOCADE treatment. Despite the optimistic outlook, concerns about competition, market access, and execution risks remain. Fair value estimates for Indivior range from $32.35 to $106.17 per share, reflecting varied investor perspectives on its future potential.

Simplywall·
US
INDV
+2.21%
UK
INDV
0.00%
Simplywall·
US
INDV
+2.21%
UK
INDV
0.00%

Indivior Study Finds Monthly Injectable Buprenorphine Lowers Relapse and Healthcare Use in OUD Patients

Indivior plc has presented new evidence on the impact of monthly injectable buprenorphine, SUBLOCADE®, for opioid use disorder (OUD) at the AMCP Nexus 2025 conference. The study shows that patients with high adherence to SUBLOCADE had lower relapse rates, reduced healthcare use, and better chronic disease management compared to those with low adherence. However, the study has limitations, including potential bias and the influence of the COVID-19 pandemic.

Reuters·
UK
INDV
0.00%
US
INDV
+2.21%
Reuters·
UK
INDV
0.00%
US
INDV
+2.21%

Laureate Education’s Earnings Call Highlights Robust Growth

Laureate Education's earnings call highlighted strong third-quarter results, with revenue of $400 million and adjusted EBITDA of $95 million, exceeding prior guidance. Enrollment grew by 7%, and the company expanded its stock repurchase program by $150 million. However, challenges include timing impacts in Peru and sluggish economic conditions in Mexico. The company raised its full-year 2025 guidance, projecting revenue between $1.681 billion and $1.686 billion. Despite challenges, Laureate remains confident in its growth and shareholder value enhancement strategies.

Tip Ranks·
US
LAUR
-1.02%
Tip Ranks·
US
LAUR
-1.02%